Medically reviewed by Dr. Ehtesham Ghani, Internal Medicine & Bariatric Medicine (ASBP). Last reviewed June 2026.
If you have been researching prescription weight-loss medications, two names come up again and again: Ozempic and Mounjaro. They belong to the same broad family of medicines, they are given as a once-weekly injection, and both have generated a great deal of attention for their effect on body weight. They are not, however, the same drug, and the way each one is approved by the FDA matters more than most online ads admit. At ThinFast MD, our Illinois physicians help patients understand the honest differences during an in-person medical exam at our Hinsdale, Arlington Heights, Brookfield, and Rockford locations.
What is the difference between Ozempic and Mounjaro?
The simplest way to tell them apart is by their active ingredient. Ozempic is the brand name for semaglutide, a GLP-1 receptor agonist. Mounjaro is the brand name for tirzepatide, which is a dual-agonist: it acts on both the GLP-1 and the GIP receptors. That second mechanism is the main structural difference between the two medications. Both work by influencing appetite signaling, slowing how quickly the stomach empties, and helping regulate blood sugar, but tirzepatide engages an additional gut hormone pathway that semaglutide does not.
It is important to be clear about what these specific brand names are approved to treat. Per their FDA prescribing information, Ozempic and Mounjaro are both approved for type 2 diabetes, not for weight management. The same molecules are sold under different brand names for weight loss: semaglutide is approved as Wegovy for chronic weight management, and tirzepatide is approved as Zepbound for the same purpose. When Ozempic or Mounjaro themselves are used purely to lose weight, that is an off-label use, while Wegovy and Zepbound are the on-label weight-management options. We think patients deserve to hear that distinction stated plainly rather than blurred together.
Which one leads to more weight loss?
Head-to-head trial data has generally favored tirzepatide. In the SURMOUNT-5 trial published in 2025 in the New England Journal of Medicine, tirzepatide (Zepbound) was compared directly with semaglutide (Wegovy) for weight management; over 72 weeks, average body-weight reduction was about 20% with tirzepatide versus about 14% with semaglutide. Earlier, the SURMOUNT-1 trial reported average reductions in body weight in the range of roughly 16% to 22.5% across the studied tirzepatide doses, while semaglutide’s STEP program reported averages in the range of about 15%, according to the published trial data and FDA labeling.
Those figures are averages from controlled clinical trials in which medication was combined with a reduced-calorie diet and increased physical activity. They are not a promise of what any single person will experience. Individual results vary, and your starting point, medical history, dose tolerance, and consistency all influence the outcome. The right medication for you is not always the one with the highest headline number in a study; it is the one that fits your health profile, your tolerance for side effects, and what is actually available to you.
Are the side effects different?
The side-effect profiles overlap a great deal. The most common reported effects for both semaglutide and tirzepatide are gastrointestinal: nausea, diarrhea, constipation, vomiting, and abdominal discomfort, which often appear early and tend to ease as the dose is increased slowly. Both carry a boxed warning in their prescribing information regarding the risk of thyroid C-cell tumors observed in rodent studies, and both are contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. This is exactly the kind of history that a thorough physician review is meant to catch before a prescription is ever written.
Why does an in-person medical exam matter for these drugs?
This is where ThinFast MD differs from the mail-order and telehealth-only services that ship semaglutide or tirzepatide after a brief online form. These are powerful metabolic medications with real contraindications and a need for ongoing supervision. Our approach starts with an in-person exam: a history and physical, laboratory work, an EKG when appropriate, and a metabolism review. That lets Dr. Ghani and our team weigh the off-label versus on-label choice, screen for the thyroid and pancreatic risks noted above, check for drug interactions, and decide whether a GLP-1 medication, a different appetite suppressant, OPTIFAST meal replacement, or another path is the better fit. You can read more on our pages covering Wegovy and Ozempic and our tirzepatide weight-loss program.
We have provided physician-supervised medical weight loss across Illinois since 1984, with offices in Hinsdale, Arlington Heights, Brookfield, and Rockford. Whether you are managing PCOS, type 2 diabetes or prediabetes, a thyroid condition, or weight changes after 50, the medication is always used as one part of a plan that includes diet, exercise, and medical supervision, never as a standalone fix.
How do I decide between Ozempic and Mounjaro?
You do not have to decide on your own, and you should not. The honest answer is that the better choice depends on your diagnosis, your insurance coverage, current product availability, how your body tolerates each medication, and your goals. Because Ozempic and Mounjaro are diabetes-approved while Wegovy and Zepbound are the weight-management approvals, the conversation also involves matching the right brand to the right clinical situation. Our physicians review pricing and insurance with you at consultation rather than quoting a number online, since coverage varies widely. To talk through which medication makes sense for you, call ThinFast MD at (708) 485-4050 to schedule an exam at any of our four Illinois locations.
Frequently asked questions
Is Ozempic or Mounjaro FDA-approved for weight loss?
Neither Ozempic nor Mounjaro is FDA-approved specifically for weight loss; both are approved for type 2 diabetes. The same molecules are approved for chronic weight management under the brand names Wegovy (semaglutide) and Zepbound (tirzepatide), per FDA prescribing information.
Does Mounjaro work better than Ozempic for weight loss?
In the head-to-head SURMOUNT-5 trial (NEJM, 2025), tirzepatide produced greater average weight reduction than semaglutide (about 20% versus about 14% at 72 weeks). These are trial averages combined with diet and exercise, and individual results vary.
What is the main difference between semaglutide and tirzepatide?
Semaglutide (Ozempic/Wegovy) is a single GLP-1 receptor agonist, while tirzepatide (Mounjaro/Zepbound) is a dual-agonist that acts on both the GLP-1 and GIP receptors. That additional pathway is the key structural difference.
Do Ozempic and Mounjaro have the same side effects?
Their side effects largely overlap, most commonly gastrointestinal effects such as nausea, diarrhea, and constipation. Both carry a boxed warning regarding thyroid C-cell tumors and are contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2, per prescribing information.
Can I get these medications without an in-person visit?
Some telehealth-only services ship them after an online form, but ThinFast MD requires an in-person exam, including history, physical, labs, and EKG when appropriate, to prescribe safely. Call (708) 485-4050 to schedule at our Hinsdale, Arlington Heights, Brookfield, or Rockford office.
This page is for educational purposes only and is not medical advice. It does not replace a consultation with a qualified clinician. Prescription weight-loss medication is prescribed only when clinically appropriate after an individual medical evaluation, and is used together with diet, exercise, and ongoing medical supervision. Individual results vary.
Find your nearest ThinFast MD clinic
We serve patients across the Chicago suburbs and Rockford. Choose your nearest location — Hinsdale, Arlington Heights, Brookfield, or Rockford — or call (708) 485-4050 to book. See all service areas.
